“Comparative Study between combination therapy Empagliflozin–Sitagliptin and Empagliflozin–Alogliptin in addition to Metformin assessing the hypoglycemic effect on patients diagnosed with malignancy and poorly controlled Type 2 diabetes mellitus as comorbidity”, JOC, vol. 24, no. 3, pp. 669–674, Sep. 2025, doi: 10.64149/J.Carcinog.24.3.669-674.